Read More

Aurinia Pharmaceuticals Announced Licensing Partner Otsuka Filed Initial Marketing Authorization Application for Voclosporin with the European Medicines Agency

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced today that the Company's licensing partner, Otsuka Pharmaceutical Europe Ltd. (OPEL), filed an initial Marketing Authorization Application (MAA) for voclosporin for the treatment of lupus nephritis (LN) to the European Medicines Agency (EMA).

AUPH